Enanta drug part of hepatitis C priority review

A drug compound codeveloped by Watertown biotech Enanta Pharmaceuticals Inc. is part of an experimental hepatitis C regimen from AbbVie Inc. that was granted priority review Friday by the Food and Drug Administration.

Enanta also said it had received $40 million in new milestone payments from AbbVie — partly because of the FDA filing — bringing to more than $150 million the amount it has received under a collaboration struck in 2006 with the North Chicago, Ill., company.

Enanta, which went public in an initial public offering last year, worked with AbbVie on a protease inhibitor that is part of an all-oral, four-drug combination the Illinois company hopes to market to treat the 3.2 million Americans infected with the hepatitis C virus.


That drug cocktail, if approved by US regulators, would compete with Gilead Science Inc.’s hepatitis C pill Sovaldi, one of the fastest-selling drugs in history.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

Drug giant Merck & Co., which agreed early this week to buy Cambridge-based Idenix Pharmaceuticals Inc. for $3.85 billion, hopes to market its own three-drug cocktail in the hepatitis C market.

Securities analysts have projected that market to generate $200 billion in sales between now and 2030.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.